Grifols Therapeutics Inc.
|Grifols Therapeutics Inc. Patent applications|
|Patent application number||Title||Published|
|20140343255||TWO-STAGE ULTRAFILTRATION/DIAFILTRATION - The present invention provides a method for concentrating a protein, in particular a method for concentrating a plasma product, in particular IgG, using glycine in a two-stage ultrafiltration/diafiltration approach.||11-20-2014|
|20140295408||COMPOSITIONS, METHODS, AND KITS FOR NUCLEIC ACID HYBRIDIZATION - Polynucleotides having a first polynucleotide segment contiguous with a second polynucleotide segment that is downstream to the first, wherein the sequence of the first polynucleotide segment is complementary to the sequence of a first probe segment of a probe for detection of a target nucleic acid sequence, wherein the sequence of the second polynucleotide segment is complementary to the sequence of a second probe segment of the probe, wherein the second probe segment is downstream to the first probe segment, are provided. The polynucleotides may be employed with dual-labeled probes (DLPs) in assays for the detection of the target nucleic acid sequences.||10-02-2014|
|20140193803||METHODS, COMPOSITIONS, AND KITS FOR DETERMINING HEPATITUS A VIRUS - The present invention relates to compositions, methods, and kits for determining the presence or absence of HAV in a sample.||07-10-2014|
|20140120526||METHODS, COMPOSITIONS, AND KITS FOR DETERMINING HUMAN IMMUNODEFICIENCY VIRUS (HIV) - The present invention relates to compositions, methods, and kits for determining the presence or absence of HIV in a sample, in particular for determining HIV-1 group M, HIV-1 group O, and/or HIV-2, in particular for simultaneous determining of HIV-1 group M, HIV-1 group O, and HIV-2.||05-01-2014|
|20140106337||METHODS, NUCLEIC ACIDS, AND KITS FOR DETECTION OF PARVOVIRUS B19 - Nucleic acid molecules derived from sequences of novel human parvovirus B19 variant genomes are provided. Also provided are assays and kits comprising the nucleic acid molecules.||04-17-2014|
|20130131192||COMPOSITION, METHOD, AND KIT FOR ALPHA-1 PROTEINASE INHIBITOR - The present invention provides compositions comprising API and at least one amino acid, in particular a liquid API formulation comprising amino acids, and methods and kits related thereto. These amino acids when incorporated into the API composition afford stability to the API formulation.||05-23-2013|
|20130053771||Therapeutic Delivery Devices, Systems, and Methods - Devices, systems, and methods for delivery of therapeutics, in particular thrombolytic agents, in particular plasmin, are provided. The devices, systems, and methods also provide for occlusion of a vessel or graft distal and/or proximal to a treatment zone. Also provided are devices, systems, and methods that trap emboli.||02-28-2013|
|20120289468||VON WILLEBRAND FACTOR (VWF)-CONTAINING PREPARATIONS, AND METHODS, KITS, AND USES RELATED THERETO - The present invention relates to methods, compositions and kits for preparing FVIII and employing same. Also provided are vWF polypeptides and nucleic acid molecules encoding same.||11-15-2012|
|20120073763||DEVICE FOR MAINTAINING STERILE INTEGRITY OF CONNECTED FLUID PATHWAYS - A device is provided for ensuring the sterile integrity of two separate fluid pathways during interconnection of the two pathways with a two-part connector assembly. The two-part connector assembly is of the type which comprises a male portion and a female portion, each portion initially having a port covered and protected by a peel-away strip. The device comprises a base assembly, a connector clamp assembly mounted to the base assembly and configured for securing the two-part connector assembly in position for interconnection of the male and female portions, and a strip withdrawal assembly mounted to the base assembly and configured for simultaneous withdrawal of the peel-away strips from the ports of the male and female portions.||03-29-2012|
Patent applications by Grifols Therapeutics Inc.